{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:34:21Z","timestamp":1790735661021,"version":"4.1.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Reactivation of fetal hemoglobin (HbF) expression is an important therapeutic option in patients with hemoglobin disorders. In sickle cell disease (SCD), an increase in HbF inhibits the polymerization of sickle hemoglobin and the resulting pathophysiology. Hydroxyurea, an inducer of HbF, has already been approved for the treatment of patients with moderate and\/or severe SCD. Recent clinical trials with other pharmacological inducers of HbF, such as butyrate and decitabine, have shown considerable promise. In this chapter, we highlight the important clinical trials with pharmacological inducers of HbF, discuss their mechanisms of action and speculate about the future of this therapeutic approach in the treatment of patients with SCD.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.58","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T23:14:02Z","timestamp":1164237242000},"page":"58-62","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":56,"title":["Induction of Fetal Hemoglobin in the Treatment of Sickle Cell Disease"],"prefix":"10.1182","volume":"2006","author":[{"given":"Hassana","family":"Fathallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Atweh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703272353700_R1","doi-asserted-by":"crossref","unstructured":"Serjeant GR. Natural history and determinants of clinical severity of sickle cell disease. Curr Opin Hematol. 1995;2:103\u2013108.","DOI":"10.1097\/00062752-199502020-00001"},{"key":"2019111703272353700_R2","doi-asserted-by":"crossref","unstructured":"Bailey K, Morris JS, Thomas P, Serjeant GR. Fetal haemoglobin and early manifestations of homozygous sickle cell disease. Arch Dis Child. 1992;67:517\u2013520.","DOI":"10.1136\/adc.67.4.517"},{"key":"2019111703272353700_R3","doi-asserted-by":"crossref","unstructured":"Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84:643\u2013649.","DOI":"10.1182\/blood.V84.2.643.643"},{"key":"2019111703272353700_R4","doi-asserted-by":"crossref","unstructured":"Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639\u20131644.","DOI":"10.1056\/NEJM199406093302303"},{"key":"2019111703272353700_R5","doi-asserted-by":"crossref","unstructured":"Ley TJ, DeSimone J, Anagnou NP, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med. 1982;307:1469\u20131475.","DOI":"10.1056\/NEJM198212093072401"},{"key":"2019111703272353700_R6","doi-asserted-by":"crossref","unstructured":"Ley TJ, DeSimone J, Noguchi CT, et al. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood. 1983;62:370\u2013380.","DOI":"10.1182\/blood.V62.2.370.bloodjournal622370"},{"key":"2019111703272353700_R7","doi-asserted-by":"crossref","unstructured":"Carr BI, Rahbar S, Asmeron Y, Riggs A, Winberg CD. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. Br J Cancer. 1988;57:395\u2013402.","DOI":"10.1038\/bjc.1988.89"},{"key":"2019111703272353700_R8","doi-asserted-by":"crossref","unstructured":"Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Nathan DG. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med. 1984;310:869\u2013873.","DOI":"10.1056\/NEJM198404053101401"},{"key":"2019111703272353700_R9","doi-asserted-by":"crossref","unstructured":"Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79:2555\u20132565.","DOI":"10.1182\/blood.V79.10.2555.2555"},{"key":"2019111703272353700_R10","doi-asserted-by":"crossref","unstructured":"Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317\u20131322.","DOI":"10.1056\/NEJM199505183322001"},{"key":"2019111703272353700_R11","doi-asserted-by":"crossref","unstructured":"Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia - the Husoft extension study. Blood. 2005.","DOI":"10.1182\/blood-2004-12-4973"},{"key":"2019111703272353700_R12","unstructured":"Kinney TR, Helms RW, O\u2019Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94:1550\u20131554."},{"key":"2019111703272353700_R13","doi-asserted-by":"crossref","unstructured":"Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74:652\u2013656.","DOI":"10.1172\/JCI111464"},{"key":"2019111703272353700_R14","doi-asserted-by":"crossref","unstructured":"Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med. 1990;322:1037\u20131045.","DOI":"10.1056\/NEJM199004123221504"},{"key":"2019111703272353700_R15","doi-asserted-by":"crossref","unstructured":"Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. Jama. 2003;289:1645\u20131651.","DOI":"10.1001\/jama.289.13.1645"},{"key":"2019111703272353700_R16","doi-asserted-by":"crossref","unstructured":"Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. 1997;89:1078\u20131088.","DOI":"10.1182\/blood.V89.3.1078"},{"key":"2019111703272353700_R17","doi-asserted-by":"crossref","unstructured":"Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001;139:790\u2013796.","DOI":"10.1067\/mpd.2001.119590"},{"key":"2019111703272353700_R18","doi-asserted-by":"crossref","unstructured":"Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103:2039\u20132045.","DOI":"10.1182\/blood-2003-07-2475"},{"key":"2019111703272353700_R19","doi-asserted-by":"crossref","unstructured":"DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood. 2002;99:3905\u20133908.","DOI":"10.1182\/blood.V99.11.3905"},{"key":"2019111703272353700_R20","doi-asserted-by":"crossref","unstructured":"Koshy M, Dorn L, Bressler L, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood. 2000;96:2379\u20132384.","DOI":"10.1182\/blood.V96.7.2379"},{"key":"2019111703272353700_R21","doi-asserted-by":"crossref","unstructured":"Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2\u2032-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 2003;102:3865\u20133870.","DOI":"10.1182\/blood-2003-05-1738"},{"key":"2019111703272353700_R22","doi-asserted-by":"crossref","unstructured":"Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on \u201cChromosomal instability and tumors promoted by DNA hypomethylation\u201d and \u201cInduction of tumors in nice by genomic hypomethylation\u201d. Science. 2003;302:1153; author reply 1153.","DOI":"10.1126\/science.1089523"},{"key":"2019111703272353700_R23","unstructured":"Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 2003;63:7089\u20137093."},{"key":"2019111703272353700_R24","doi-asserted-by":"crossref","unstructured":"Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 1995;81:197\u2013205.","DOI":"10.1016\/0092-8674(95)90329-1"},{"key":"2019111703272353700_R25","doi-asserted-by":"crossref","unstructured":"Atweh GF, Schechter AN. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol. 2001;8:123\u2013130.","DOI":"10.1097\/00062752-200103000-00010"},{"key":"2019111703272353700_R26","unstructured":"Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999;93:1790\u20131797."},{"key":"2019111703272353700_R27","doi-asserted-by":"crossref","unstructured":"Sher GD, Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med. 1995;332:1606\u20131610.","DOI":"10.1056\/NEJM199506153322404"},{"key":"2019111703272353700_R28","doi-asserted-by":"crossref","unstructured":"Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood. 1994;84:339\u2013343.","DOI":"10.1182\/blood.V84.1.339.339"},{"key":"2019111703272353700_R29","doi-asserted-by":"crossref","unstructured":"Resar LM, Segal JB, Fitzpatric LK, Friedmann A, Brusilow SW, Dover GJ. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediatr Hematol Oncol. 2002;24:737\u2013741.","DOI":"10.1097\/00043426-200212000-00011"},{"key":"2019111703272353700_R30","doi-asserted-by":"crossref","unstructured":"Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A. 1984;81:6993\u20136997.","DOI":"10.1073\/pnas.81.22.6993"},{"key":"2019111703272353700_R31","doi-asserted-by":"crossref","unstructured":"Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2\u2032-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A. 1994;91:11797\u201311801.","DOI":"10.1073\/pnas.91.25.11797"},{"key":"2019111703272353700_R32","doi-asserted-by":"crossref","unstructured":"Ghoshal K, Datta J, Majumder S, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol. 2005;25:4727\u20134741.","DOI":"10.1128\/MCB.25.11.4727-4741.2005"},{"key":"2019111703272353700_R33","doi-asserted-by":"crossref","unstructured":"Lavelle D, Vaitkus K, Hankewych M, Singh M, DeSimone J. Effect of 5-aza-2\u2032-deoxycytidine (Dacogen) on covalent histone modifications of chromatin associated with the epsilon-, gamma-, and beta-globin promoters in Papio anubis. Exp Hematol. 2006;34:339\u2013347.","DOI":"10.1016\/j.exphem.2005.12.010"},{"key":"2019111703272353700_R34","doi-asserted-by":"crossref","unstructured":"Weinberg RS, Ji X, Sutton M, et al. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood. 2005;105:1807\u20131809.","DOI":"10.1182\/blood-2004-02-0454"},{"key":"2019111703272353700_R35","doi-asserted-by":"crossref","unstructured":"Ikuta T, Ausenda S, Cappellini MD. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci U S A. 2001;98:1847\u20131852.","DOI":"10.1073\/pnas.98.4.1847"},{"key":"2019111703272353700_R36","doi-asserted-by":"crossref","unstructured":"Pace BS, Qian XH, Sangerman J, et al. p38 MAP kinase activation mediates gamma-globin gene induction in erythroid progenitors. Exp Hematol. 2003;31:1089\u20131096.","DOI":"10.1016\/S0301-472X(03)00235-2"},{"key":"2019111703272353700_R37","doi-asserted-by":"crossref","unstructured":"Chenais B. Requirement of GATA-1 and p45 NF-E2 expression in butyric acid-induced erythroid differentiation. Biochem Biophys Res Commun. 1998;253:883\u2013886.","DOI":"10.1006\/bbrc.1998.9869"},{"key":"2019111703272353700_R38","doi-asserted-by":"crossref","unstructured":"Partington GA, Patient RK. Phosphorylation of GATA-1 increases its DNA-binding affinity and is correlated with induction of human K562 erythroleukaemia cells. Nucleic Acids Res. 1999;27:1168\u20131175.","DOI":"10.1093\/nar\/27.4.1168"},{"key":"2019111703272353700_R39","doi-asserted-by":"crossref","unstructured":"Gavva NR, Wen SC, Daftari P, et al. NAPP2, a peroxisomal membrane protein, is also a transcriptional corepressor. Genomics. 2002;79:423\u2013431.","DOI":"10.1006\/geno.2002.6714"},{"key":"2019111703272353700_R40","doi-asserted-by":"crossref","unstructured":"Ozawa Y, Towatari M, Tsuzuki S, et al. Histone deacetylase 3 associates with and represses the transcription factor GATA-2. Blood. 2001;98:2116\u20132123.","DOI":"10.1182\/blood.V98.7.2116"},{"key":"2019111703272353700_R41","doi-asserted-by":"crossref","unstructured":"Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol. 2005;33:259\u2013271.","DOI":"10.1016\/j.exphem.2004.11.007"},{"key":"2019111703272353700_R42","doi-asserted-by":"crossref","unstructured":"Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003;111:231\u2013239.","DOI":"10.1172\/JCI200316672"},{"key":"2019111703272353700_R43","doi-asserted-by":"crossref","unstructured":"Nahavandi M, Tavakkoli F, Wyche MQ, Perlin E, Winter WP, Castro O. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. Br J Haematol. 2002;119:855\u2013857.","DOI":"10.1046\/j.1365-2141.2002.03919.x"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/58\/1091502\/058_062ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/58\/1091502\/058_062ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:27:40Z","timestamp":1573979260000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/58\/19763\/Induction-of-Fetal-Hemoglobin-in-the-Treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.58","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}